Did You Know...
...that the video game, Pong, was invented by a guy who graduated at the bottom of his engineering class? Nolan Bushnell spent more time running the games at a local amusement park than he did on his studies at the University of Utah. His dreams of working for Disney's amusement empire were dashed when the company wouldn't hire him. Taking a boring job, Nolan daydreamed about electronic versions of popular games. He invented Pong, the first video game, and went on to found Atari Co.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8017132 | Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide... | 09/13/2011 |
| 7790185 | Method for the production of bacterial toxins Methods and compositions are provided for the enhanced production of bacterial toxins in large-scale cultures. Specifically, methods and compositions for reducing bacterial toxin expression inhibitors are providing including, but not limited to, addition of toxin ex... | 09/07/2010 |
| 7666436 | Pertussis toxin mutants, Bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the amino acid residues Glu129, Asp11, Trp26, Arg9, Phe50, Asp1, Arg13, Tyr130, Gly86, Ile88, Tyr89, Tyr8, Gly44, Thr... | 02/23/2010 |
| 7427404 | Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the aminoacid residues Glu129, Asp11, Trp26, Arg9, Phe50, Asp1, Arg13, Tyr130, Gly86, Ile88, Tyr89, Tyr8, Gly 44, Thr... | 09/23/2008 |
| 7410646 | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating a microorganism transformed with a hybrid plasmid including the gene/... | 08/12/2008 |
| 7323183 | Vaccine compositions including chitosan for intranasal administration and use thereof There is provided vaccine compositions for intranasal administration, which compositions comprise one or more antigens and an effective adjuvant amount of a chitosan. ... | 01/29/2008 |
| 7279169 | Mucosal DTPa vaccines Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT) or E. coli heat labile toxin (LT). Component (b) acts as a muco... | 10/09/2007 |
| 7267963 | Modified plant viruses and methods of use thereof The present invention relates to modulating the nature and/or level of an immune response to a molecule. In particular, the invention relates to effecting an increase in the TH1 immune response to molecules such as, but not limited to, antigens or immunogens. The in... | 09/11/2007 |
| 7232671 | Pertussis toxin gene: cloning and expression of protective antigen A cloned gene encoding the expression of an antigenic mutant pertussis toxin with substantially reduced enzymatic activity has been described. ... | 06/19/2007 |
| 7211263 | Use of adenylate cyclase or bacteria producing it as vaccines against The invention relates to a method of immunizing a mammal against infection by a first Bordetella species. The method comprises administering to the mammal a preparation comprising a portion of the amino acid sequence of mature adenylate cyclase of a second | 05/01/2007 |
| RE39494 | Inactivated mycoplasma hyopneumoniae and uses therefor The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The r... | 02/27/2007 |
| 7172762 | antigens and vaccine compositions The invention relates to stabilized antigen compositions of Erysipelothrix rhusiopathiae and vaccine formulations containing such antigen compositions. Antigens of the invention are effective in providing long-term protection against erysipelas in animals. | 02/06/2007 |
| 7144576 | Modified toxin The development of subunits and subunit analogs of the Bordetella exotoxin by recombinant DNA techniques provides vaccine products that retain their biological activity, are highly immunogenic, and can confer protection against disease challenge. Genetically-... | 12/05/2006 |
| 7105161 | Proteinaceous adjuvants A modulated immune response to an antigen is achieved by coadministering the antigen and a genetically-detoxified pertussis holotoxin, particularly one retaining its immunogenicity, to a host. The modulated immune response enables immunogenic compositions, in... | 09/12/2006 |
| 7105317 | Immunogenic compositions comprising vrg-gene products from extracts This invention relates to an immunogenic composition comprising a bacterial extract containing at least one expression products of the vrg genes of a strain of Bordetella chosen from B. pertussis, B. parapertussis, or B. bronchiseptica. The inve... | 09/12/2006 |
| 7090853 | Noscapine derivatives as adjuvant compositions and methods of use thereof An adjuvant composition comprising noscapine and its derivatives, for use in the treatment of tumors, cancer, as an adjuvant for vaccines. ... | 08/15/2006 |
| 7087236 | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof A method of inducing either a TH1 polarized immune response, a TH2 polarized immune response or a combined TH1 and TH2 response to an antigen and associated vaccine formulations are disclosed. A method is provided for indu... | 08/08/2006 |
| 7070781 | Nontoxic mucosal adjuvant A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating t... | 07/04/2006 |
| 7070779 | POLYPEPTIDES CONTAINING POLYMORPHISMS OF THE REPEATED REGIONS OF PERTACTIN IN BORDETELLA PERTUSSIS, BORDETELLA PARAPERTUSSIS, AND BORDETELLA BRONCHISEPTICA, THEIR USE IN DIAGNOSTICS, AND IN IMMUNOGENIC COMPOSITIONS Pertactin (PRN) is an outer membrane protein expressed by Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica, which induces protective immunity to Bordetella infections. The immunodominant and immunoprotective epitopes... | 07/04/2006 |
| 7056521 | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labile E. coli (LT). ... | 06/06/2006 |
| 7045314 | Method for the production of bacterial toxins Methods and compositions are provided for the enhanced production of bacterial toxins in large-scale cultures. Specifically, methods and compositions for reducing bacterial toxin expression inhibitors are providing including, but not limited to, addition of toxin ex... | 05/16/2006 |
| 7037499 | Adjuvant for transcutaneous immunization A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune re... | 05/02/2006 |
| 6858211 | Vaccines against Escherichia coli O157 infection This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including... | 02/22/2005 |
| 6814971 | Adjuvants for use in vaccines The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal. ... | 11/09/2004 |
| 6713072 | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating, a microorganism transformed with a hybrid plasmid including the gene... | 03/30/2004 |
| 6582705 | Acellular antibordetella vaccine The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of Bordetella chosen from B. pertussis, B. parapertussis or B bronc... | 06/24/2003 |
| 6562352 | Vaccine compositions for mucosal delivery The invention provides the use of an antigen which is a mucosally immunogenically active substance comprising the 50 kD C fragment of tetanus toxin, an immunogenic fragment thereof, or a derivative thereof formed by amino acid deletion, substitution or in... | 05/13/2003 |
| 6548287 | Non-pyrogenic bacterial strains and use of the same The present invention provides gram-negative bacterial strains that produce substantially pure non-pyrogenic lipopolysaccharide or lipid A. The present invention also relates to a use of said strains for the preparation of non-pyrogenic DNA and use of the... | 04/15/2003 |
| 6517844 | Compositions and method for immunizing polutry The present invention is directed to vaccine compositions and methods for immunizing poultry. The vaccine compositions comprise inactivated bacterial organisms which can be administered to the poultry through oral intake of water.... | 02/11/2003 |
| 6514499 | Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof Compositions characterized by ADP-ribosyltransferase activity are useful in promoting prophylactic and/or therapeutic responses as are promoted by, e.g., pertussis toxin but directed against another target antigen (e.g., a cancer-related antigen) in a mam... | 02/04/2003 |
| 6451338 | Liposomes containing particulate materials A method is provided for the formation of liposomes of 0.1 μm to 50 μm in diameter having unilamella or multilamella structure and containing water insoluble or undissolved particulate materials comprising (a) forming liposomes and removing substantiall... | 09/17/2002 |
| 6440423 | Mutant enterotoxin effective as a non-toxic oral adjuvant Methods and compositions are provided herein for the se of a novel mutant form of E. coli heat-labile enterotoxin which has lost its toxicity but has retained its immunologic activity. This enterotoxin is used in combination with an unrelated antigen to a... | 08/27/2002 |
| 6399076 | Acellular pertussis vaccines and methods of preparation thereof Acellular pertussis vaccines comprise purified toxin or toxoid thereof, filamentous haemagglutinin, pertactin and fimbrial agglutinogens formulated to confer protection to at least 70% of members of an at-risk population. The fimbrial agglutinogens may be... | 06/04/2002 |
| 6391318 | Vaccine compositions including chitosan for intranasal administration and use thereof A variety of different types of nasal vaccine systems have been described including cholera toxin, microspheres, nanoparticles, liposomes, attenuated virus, and outer membrane proteins (proteosomes). The present invention is directed toward a novel nasal ... | 05/21/2002 |
| 6387377 | Acellular antibordetella vaccine The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of Bordetella chosen from B. Tertussis, B. parapertussis or B. bron... | 05/14/2002 |
| 6379676 | Enhancing immune response in animals A method for improving the immune response of an animal to a vaccine, comprising: feeding an animal a diet of contamination-resistant feed, and treating said animal with an anti-viral or anti-bacterial vaccine.... | 04/30/2002 |
| 6368589 | Use of autologous promoters to express gene products in Bordetella Autologous promoters are used to effect expression of gene products in Bordetella strains. Hybrid Bordetella genes are constructed comprising a Bordetella gene, particularly one encoding a Bordetella antigen, fused at an ATG codon to a native but autologo... | 04/09/2002 |
| 6322809 | Liposomes containing particulate materials A method is provided for the formation of liposomes of 0.1 μm to 50 μm in diameter having unilamella or multilamella structure and containing water insoluble or undissolved particulate materials comprising (a) forming liposomes and removing substantiall... | 11/27/2001 |
| 6309648 | Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections The subject of the invention is amino acid sequences of the AC-Hly from B. pertussis. B. parapertussis and/or B. bronchiseptica, carrying epitopes capable of inducing a protective immune response against infection by Bordetella. The subject of the inventi... | 10/30/2001 |
| 6299881 | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts A method for producing a conjugate vaccine includes mixing a uronium salt reagent with a first moiety (e.g., a polysaccharide). According to the invention, the uronium salt reagent has a chemical structure corresponding to formula I: ##STR1## wherein... | 10/09/2001 |
